# Efficacy and Safety of Intramuscular HBIG Grifols for the Prevention of Recurrence After Liver Transplantation

> **NCT00895713** · PHASE2 · COMPLETED · sponsor: **Instituto Grifols, S.A.** · enrollment: 18 (actual)

## Conditions studied

- Hepatitis B, Chronic

## Interventions

- **DRUG:** intramuscular hepatitis B virus immune globulin

## Key facts

- **NCT ID:** NCT00895713
- **Lead sponsor:** Instituto Grifols, S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-11
- **Primary completion:** 2005-06
- **Final completion:** 2005-07
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2009-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00895713

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00895713, "Efficacy and Safety of Intramuscular HBIG Grifols for the Prevention of Recurrence After Liver Transplantation". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00895713. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*